Cardiac resynchronisation therapy can significantly delay the progression of heart failure, latest study results suggest.
US researchers studied 1,820 patients with early stage, mild heart failure from 110 centres in the US, Canada and Europe.
Half received an implanted defibrillator, and the rest received a defibrillator plus cardiac resynchronisation – a device implanted in the upper chest which delivers electrical impulses that help synchronise contractions in the left ventricle.
The researchers found that patients who had a defibrillator plus cardiac resynchronisation had a significantly improved heart pumping efficiency compared to those with just a defibrillator.
The study also found that, compared to the control group, those who received cardiac resynchronisation had a 41% lower risk of heart failure events requiring hospitalisation or outpatient treatment with intravenous drugs.
“This shows, for the first time, that the onset of heart failure symptoms and hospitalisation for heart failure can be delayed with pacing therapy,” the authors said at the European Society of Cardiology Congress in Barcelona, Spain, this week.